| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 37.7 | 32.5 |
| Net income | -35.6 | -51.2 |
| EPS (diluted, $ a share) | $-0.36 | $-0.52 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +16.0% |
|---|---|
| Operating margin | -90.6% |
10-Q filed with the SEC, NASDAQ: SPRY. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
ARS Pharmaceuticals, Inc.: key numbers
- Share price
- $3.59Close, Nov 16
- Market cap
- $361M
- Shares outstanding
- 100.53MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from ARS Pharmaceuticals, Inc.
All →ARS Pharmaceuticals Financial Results
ARS Pharmaceuticals reported Q3 2026 financial results with total revenue of $37.7 million, driven by $33.4 million in U.S. net product revenue for neffy. The company achieved a 5% overall U.S. market share for neffy and reaffirmed its path to cash flow breakeven by year-end 2027.
- Term
- Q3 2026
“In August, we committed to three corporate priorities – steady market share gains with neffy, greater financial discipline with a path to cash flow breakeven by year-end 2027, and expansion of our needle-free epinephrine platform beyond anaphylaxis. I’m proud to report that our team has delivered on each.”
Donn Casale, President and Chief Executive Officer
“neffy is a highly differentiated product in a large market with genuine demand, and I am confident it can become the standard of care in the epinephrine market.”
Meg Smith, Chief Commercial Officer